WntResearch’s CEO on the option program and the NeoFox study
The development company WntResearch is currently in the process of redeeming the TO5 warrant. The capital injection is made to continue the phase IIb study with the drug candidate Foxy-5. In connection with the BioStock Investor Meeting, the company’s CEO Pernilla Sandwall talked about the option program, changes in the study plan and the outcome of the company’s issue.
See the interview with WntResearch CEO Pernilla Sandwall below:
See Pernilla Sandwall’s company presentation from the BioStock Investor Meeting below:The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.